Literature DB >> 28306680

Anaesthesia in patients with liver disease.

Malgorzata H Starczewska1, Wint Mon, Peter Shirley.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to summarize the most recent up to date research data and recommendations regarding anaesthetic management of patients with liver disease undergoing surgery. The incidence of chronic liver disease (CLD) continues to rise and perioperative mortality and morbidity remains unacceptably high in this group. Meticulous preoperative assessment and carefully planned anaesthetic management are vital in improving outcomes in patients with liver disease undergoing surgery. RECENT
FINDINGS: The presence of cirrhosis is associated with a significantly increased risk of postoperative morbidity and mortality in patients undergoing elective surgery. The Child--Pugh--Turcotte scale and model for end-stage liver disease (MELD) score remain the most commonly applied scoring systems in preoperative risk assessment, but new MELD-based indices and novel scoring systems might offer better prognostic value. Propofol and new inhalational agents (sevoflurane, desflurane) are recommended hypnotic agents. The titration of opiates in the perioperative period is recommended because of their altered metabolism in patients with liver disease. Perioperative management should include close haemodynamic monitoring and admission to a critical care area should be considered.
SUMMARY: Patients with liver disease undergoing anaesthesia pose significant challenges and advanced planning and preparation are required in order to improve perioperative outcomes in this group. VIDEO ABSTRACT: http://links.lww.com/COAN/A43.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28306680     DOI: 10.1097/ACO.0000000000000470

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  8 in total

Review 1.  Roles of neutrophil reactive oxygen species (ROS) generation in organ function impairment in sepsis.

Authors:  Jiaqi Lu; Jingyuan Liu; Ang Li
Journal:  J Zhejiang Univ Sci B       Date:  2022-06-15       Impact factor: 5.552

Review 2.  Perioperative Evaluation and Management of Patients With Cirrhosis: Risk Assessment, Surgical Outcomes, and Future Directions.

Authors:  Kira L Newman; Kay M Johnson; Paul B Cornia; Peter Wu; Kamal Itani; George N Ioannou
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-31       Impact factor: 11.382

3.  Efficacy and Safety of Remimazolam Tosilate versus Propofol for General Anesthesia in Cirrhotic Patients Undergoing Endoscopic Variceal Ligation.

Authors:  Fu Shi; Yanjie Chen; Hongtao Li; Yang Zhang; Tonghang Zhao
Journal:  Int J Gen Med       Date:  2022-01-13

4.  Perioperative management of liver surgery-review on pathophysiology of liver disease and liver failure.

Authors:  Lukas Gasteiger; Stephan Eschertzhuber; Werner Tiefenthaler
Journal:  Eur Surg       Date:  2018-04-13       Impact factor: 0.953

5.  Same-Day versus Overnight Observation after Outpatient Pediatric Percutaneous Liver Biopsy: A Retrospective Cohort Study.

Authors:  Svetlana Yuryevna Kozlovich; Anthony Alexander Sochet; Sorany Son; Michael John Wilsey
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2019-06-18

6.  A Simple and Quick Screening Method for Intrapulmonary Vascular Dilation in Cirrhotic Patients Based on Machine Learning.

Authors:  Yu-Jie Li; Kun-Hua Zhong; Xue-Hong Bai; Xi Tang; Peng Li; Zhi-Yong Yang; Hong-Yu Zhi; Xiao-Jun Li; Yang Chen; Peng Deng; Xiao-Lin Qin; Jian-Teng Gu; Jiao-Lin Ning; Kai-Zhi Lu; Ju Zhang; Zheng-Yuan Xia; Yu-Wen Chen; Bin Yi
Journal:  J Clin Transl Hepatol       Date:  2021-04-29

Review 7.  Perioperative management of patients with liver disease for non-hepatic surgery: A systematic review.

Authors:  Atsedu Endale Simegn; Debas Yaregal Melesse; Yosef Belay Bizuneh; Wudie Mekonnen Alemu
Journal:  Ann Med Surg (Lond)       Date:  2022-02-24

8.  Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment.

Authors:  Yue Hu; Xiaojiao Li; Jingrui Liu; Hong Chen; Wenbo Zheng; Hong Zhang; Min Wu; Cuiyun Li; Xiaoxue Zhu; Jinfeng Lou; Pangke Yan; Nan Wu; Xiao Liu; Shiping Ma; Xu Wang; Yanhua Ding; Chengluan Xuan
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.